Mylan declines Senate committee request to testify about EpiPen

(Reuters) - Mylan NV has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.

Mylan declines Senate committee request to testify about EpiPen
Read More


Bagikan Berita Ini